P. Solal-céligny, P. Roy, and P. Colombat, Follicular Lymphoma International Prognostic Index, Blood, vol.104, issue.5, pp.1258-126510, 2004.
DOI : 10.1182/blood-2003-12-4434

M. Federico, M. Bellei, and L. Marcheselli, Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project, Journal of Clinical Oncology, vol.27, issue.27, pp.4555-4562, 2009.
DOI : 10.1200/JCO.2008.21.3991

A. Pastore, V. Jurinovic, and R. Kridel, Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet Oncology, vol.16, issue.9, pp.1111-112210, 2015.
DOI : 10.1016/S1470-2045(15)00169-2

L. Pasqualucci, H. Khiabanian, and M. Fangazio, Genetics of Follicular Lymphoma Transformation, Cell Reports, vol.6, issue.1, pp.130-140, 2014.
DOI : 10.1016/j.celrep.2013.12.027

C. Correia, P. Schneider, and H. Dai, BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma, Blood, vol.125, issue.4, pp.658-667, 2015.
DOI : 10.1182/blood-2014-04-571786

G. Salles, J. Seymour, and F. Offner, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, issue.9759, pp.42-51, 2011.
DOI : 10.1016/S0140-6736(10)62175-7

J. He, O. Abdel-wahab, and M. Nahas, Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood, 2016.

B. Cheson, S. Horning, and B. Coiffier, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, Journal of Clinical Oncology, vol.17, issue.4, p.1244, 1999.
DOI : 10.1200/JCO.1999.17.4.1244

J. Okosun, C. Bödör, and J. Wang, Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma, Nature Genetics, vol.61, issue.2, pp.176-181, 2014.
DOI : 10.1371/journal.pgen.1002691

J. Schuetz, N. Johnson, and R. Morin, BCL2 mutations in diffuse large B-cell lymphoma, Leukemia, vol.15, issue.6, 2012.
DOI : 10.1074/jbc.M507611200

F. Gnad, A. Baucom, K. Mukhyala, G. Manning, and Z. Zhang, Assessment of computational methods for predicting the effects of missense mutations in human cancers, BMC Genomics, vol.14, pp.10-1186, 2013.

B. Reva, Y. Antipin, and C. Sander, Predicting the functional impact of protein mutations: application to cancer genomics, Nucleic Acids Research, vol.39, issue.17, pp.118-118, 2011.
DOI : 10.1093/nar/gkr407

M. Green, A. Gentles, and R. Nair, Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma, Blood, vol.121, issue.9, pp.1604-1611, 2013.
DOI : 10.1182/blood-2012-09-457283

R. Burkhard, G. Bhagat, and S. Cogliatti, BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma, Hematol Oncol, 2014.

J. Lohr, P. Stojanov, and M. Lawrence, Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing, Proceedings of the National Academy of Sciences, vol.79, issue.1, pp.3879-3884, 2012.
DOI : 10.1182/blood-2007-07-100115

M. Takahashi, H. Saito, K. Atsukawa, H. Ebinuma, T. Okuyama et al., Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells, Hepatology Research, vol.25, issue.2, pp.192-201, 2003.
DOI : 10.1016/S1386-6346(02)00244-9

T. Miyashita and J. Reed, Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line, Blood, vol.81, issue.1, pp.151-157, 1993.

D. Pérez-callejo, J. González-rincón, A. Sánchez, M. Provencio, and M. Sánchez-beato, Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas, Cancer Treatment Reviews, vol.41, issue.8, pp.680-689, 2015.
DOI : 10.1016/j.ctrv.2015.05.007

C. Sarkozy, M. Trneny, and L. Xerri, Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial, Journal of Clinical Oncology, vol.34, issue.22, 2016.
DOI : 10.1200/JCO.2015.65.7163
URL : https://hal.archives-ouvertes.fr/hal-01455586